<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340519</url>
  </required_header>
  <id_info>
    <org_study_id>CIN_EarlyMRCrohns</org_study_id>
    <nct_id>NCT03340519</nct_id>
  </id_info>
  <brief_title>Early MRI Prediction of Crohns</brief_title>
  <official_title>Early MRI Prediction of Response to Medical Therapy and Mucosal Healing in Small Bowel Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan a prospective study designed to optimize and translate noncontrast,
      novel Magnetic Resonance Imaging (MRI) techniques for detecting and measuring intestinal
      inflammation as well as for allowing early prediction of response to medical therapy in small
      bowel Crohn's Disease (CD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to evaluate novel MRI techniques to measure: 1) mesenteric/intestinal
      blood flow using phase-contrast cine MRI, 2) intestinal motility (peristalsis) using dynamic
      cine MRI, and 3) bowel wall perfusion and molecular water diffusion. Precise objective
      measurements of diseased bowel blood flow (in ml/min) and bowel motility (in contractions per
      minute) are not currently used in the clinical care of CD patients, while diffusion-weighted
      imaging is typically used in a qualitative manner. None of these techniques have been
      evaluated for predicting eventual response to therapy or correlated with endoscopic mucosal
      healing in pediatric or adult CD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of therapeutic response in patients with Crohns disease</measure>
    <time_frame>30 minutes</time_frame>
    <description>Assess novel MRI techniques for ability to predict early response to infliximab therapy in 20 newly diagnosed small bowel CD patients.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newly Diagnosed Crohns Patients</arm_group_label>
    <description>MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR Imaging</intervention_name>
    <description>Novel MR imaging will be performed to provide bowel anatomic and functional data</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Newly Diagnosed Crohns Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Control Group General population Newly Diagnosed Crohns Group Cincinnati Children's
        Inflammatory Bowel Disease Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Control Group

        -Be able to tolerate up to 45 minutes in an MRI scanner

        Newly Diagnosed Crohns Group

          -  Newly diagnosed, pathology-confirmed diagnosis of small bowel Crohn's disease,

          -  Expected to receive infliximab (Remicade; Janssen Biotech, Inc.) or other anti-Tumor
             Necrosis Factor (anti-TNF) medical therapy,

          -  Between 11 to 25 years of age and able to assent/consent,

          -  Be available for follow-up MRI at 4-weeks and 6-months after the initiation of
             treatment,

          -  Be able to tolerate up to 45 minutes in an MRI scanner.

        Exclusion Criteria:

        Healthy Control Group

          -  Inability to obtain assent/consent,

          -  Inability to tolerate 45 minutes in an MRI scanner,

          -  Contraindication to MRI (e.g., MRI incompatible implant or support device),

          -  Previous (remote) diagnosis or treatment of inflammatory bowel disease or other
             intestinal disease,

          -  History of intra-abdominal surgery, including surgery on the intestine,

          -  Pregnancy. Point-of-care urine pregnancy testing will be performed on all female study
             participants of reproductive potential (pediatric and adult) prior to each research
             MRI exam.

        Newly Diagnosed Crohns Group

          -  Inability to obtain assent/consent,

          -  Inability to tolerate 45 minutes in an MRI scanner,

          -  Contraindication to MRI (e.g., MRI incompatible implant or support device),

          -  Previous (remote) diagnosis or treatment of inflammatory bowel disease,

          -  History of intra-abdominal surgery, including surgery on the intestine,

          -  Known bleeding disorder/coagulopathy (contraindication for adult subjects, as this may
             increase the risk of research colonoscopy),

          -  Pregnancy. Point-of-care urine pregnancy testing will be performed on all female study
             participants of reproductive potential (pediatric and adult) prior to each research
             MRI exam.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan R Dillman, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Becky Imbus, BA</last_name>
    <phone>513-636-9403</phone>
    <email>rebecca.imbus@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan R Dillman, MD, MSc</last_name>
    <phone>513-803-7114</phone>
  </overall_contact_backup>
  <reference>
    <citation>Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb;105(2):289-97. doi: 10.1038/ajg.2009.579. Epub 2009 Oct 27. Review.</citation>
    <PMID>19861953</PMID>
  </reference>
  <reference>
    <citation>Aggarwal D, Limdi JK. Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2015 Jan;27(1):13-9. doi: 10.1097/MEG.0000000000000222.</citation>
    <PMID>25341058</PMID>
  </reference>
  <reference>
    <citation>Church PC, Guan J, Walters TD, Frost K, Assa A, Muise AM, Griffiths AM. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis. 2014 Jul;20(7):1177-86. doi: 10.1097/MIB.0000000000000083.</citation>
    <PMID>24865777</PMID>
  </reference>
  <reference>
    <citation>Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Kay M, Crandall W, Oliva-Hemker M, Keljo D, LeLeiko N, Markowitz J; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009 Jun;15(6):816-22. doi: 10.1002/ibd.20845.</citation>
    <PMID>19107783</PMID>
  </reference>
  <reference>
    <citation>Kane SV, Jaganathan S, Bedenbaugh AV, Palmer L, Schwartz DA. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease. Curr Med Res Opin. 2014 Sep;30(9):1821-6. doi: 10.1185/03007995.2014.928273. Epub 2014 Jun 2.</citation>
    <PMID>24884302</PMID>
  </reference>
  <reference>
    <citation>Mandel MD, Miheller P, MÃ¼llner K, Golovics PA, Lakatos PL. Have biologics changed the natural history of Crohn's disease? Dig Dis. 2014;32(4):351-9. doi: 10.1159/000358135. Epub 2014 Jun 23. Review.</citation>
    <PMID>24969279</PMID>
  </reference>
  <reference>
    <citation>Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S, Conte F, Cucchiara S. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol. 2009 Oct;104(10):2566-71. doi: 10.1038/ajg.2009.372. Epub 2009 Jun 23.</citation>
    <PMID>19550415</PMID>
  </reference>
  <reference>
    <citation>Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS; PRO-KIIDS Research Group. Increased effectiveness of early therapy with anti-tumor necrosis factor-Î± vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014 Feb;146(2):383-91. doi: 10.1053/j.gastro.2013.10.027. Epub 2013 Oct 23.</citation>
    <PMID>24162032</PMID>
  </reference>
  <reference>
    <citation>Dillman JR, Adler J, Zimmermann EM, Strouse PJ. CT enterography of pediatric Crohn disease. Pediatr Radiol. 2010 Jan;40(1):97-105. doi: 10.1007/s00247-009-1465-5. Epub 2009 Nov 20. Review.</citation>
    <PMID>19936733</PMID>
  </reference>
  <reference>
    <citation>Mollard BJ, Smith EA, Dillman JR. Pediatric MR enterography: technique and approach to interpretation-how we do it. Radiology. 2015 Jan;274(1):29-43. doi: 10.1148/radiol.14122449.</citation>
    <PMID>25531478</PMID>
  </reference>
  <reference>
    <citation>Brenner DJ. Should computed tomography be the modality of choice for imaging Crohn's disease in children? The radiation risk perspective. Gut. 2008 Nov;57(11):1489-90. doi: 10.1136/gut.2008.156265.</citation>
    <PMID>18941001</PMID>
  </reference>
  <reference>
    <citation>Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007 Nov 29;357(22):2277-84. Review.</citation>
    <PMID>18046031</PMID>
  </reference>
  <reference>
    <citation>McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015 Jun;275(3):772-82. doi: 10.1148/radiol.15150025. Epub 2015 Mar 5.</citation>
    <PMID>25742194</PMID>
  </reference>
  <reference>
    <citation>Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC. High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. Radiology. 2015 Sep;276(3):836-44. doi: 10.1148/radiol.2015150872. Epub 2015 Jun 16.</citation>
    <PMID>26079490</PMID>
  </reference>
  <reference>
    <citation>Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1042-50.e2. doi: 10.1016/j.cgh.2013.09.006. Epub 2013 Sep 10. Review.</citation>
    <PMID>24036054</PMID>
  </reference>
  <reference>
    <citation>Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016 Feb;43(3):317-33. doi: 10.1111/apt.13475. Epub 2015 Nov 25. Review.</citation>
    <PMID>26607562</PMID>
  </reference>
  <reference>
    <citation>Reinink AR, Lee TC, Higgins PD. Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis. Inflamm Bowel Dis. 2016 Aug;22(8):1859-69. doi: 10.1097/MIB.0000000000000816. Review.</citation>
    <PMID>27206015</PMID>
  </reference>
  <reference>
    <citation>Nayak KS, Nielsen JF, Bernstein MA, Markl M, D Gatehouse P, M Botnar R, Saloner D, Lorenz C, Wen H, S Hu B, Epstein FH, N Oshinski J, Raman SV. Cardiovascular magnetic resonance phase contrast imaging. J Cardiovasc Magn Reson. 2015 Aug 9;17:71. doi: 10.1186/s12968-015-0172-7. Review.</citation>
    <PMID>26254979</PMID>
  </reference>
  <reference>
    <citation>Heiss SG, Li KC. Magnetic resonance angiography of mesenteric arteries. A review. Invest Radiol. 1998 Sep;33(9):670-81. Review.</citation>
    <PMID>9766052</PMID>
  </reference>
  <reference>
    <citation>Ãkerman A, MÃ¥nsson S, Fork FT, Leander P, Ekberg O, Taylor S, Menys A, Ohlsson B. Computational postprocessing quantification of small bowel motility using magnetic resonance images in clinical practice: An initial experience. J Magn Reson Imaging. 2016 Aug;44(2):277-87. doi: 10.1002/jmri.25166. Epub 2016 Jan 23.</citation>
    <PMID>26801196</PMID>
  </reference>
  <reference>
    <citation>Bickelhaupt S, Pazahr S, Chuck N, Blume I, Froehlich JM, Cattin R, Raible S, Bouquet H, Bill U, Rogler G, Frei P, Boss A, Patak MA. Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin. Neurogastroenterol Motil. 2013 Jun;25(6):467-73. doi: 10.1111/nmo.12088. Epub 2013 Mar 18.</citation>
    <PMID>23495824</PMID>
  </reference>
  <reference>
    <citation>Froehlich JM, Waldherr C, Stoupis C, Erturk SM, Patak MA. MR motility imaging in Crohn's disease improves lesion detection compared with standard MR imaging. Eur Radiol. 2010 Aug;20(8):1945-51. doi: 10.1007/s00330-010-1759-x. Epub 2010 Apr 9.</citation>
    <PMID>20379822</PMID>
  </reference>
  <reference>
    <citation>Menys A, Atkinson D, Odille F, Ahmed A, Novelli M, Rodriguez-Justo M, Proctor I, Punwani S, Halligan S, Taylor SA. Quantified terminal ileal motility during MR enterography as a potential biomarker of Crohn's disease activity: a preliminary study. Eur Radiol. 2012 Nov;22(11):2494-501. doi: 10.1007/s00330-012-2514-2. Epub 2012 Jun 3.</citation>
    <PMID>22661057</PMID>
  </reference>
  <reference>
    <citation>Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am. 2006 Nov;16(4):619-32, viii-ix. Review.</citation>
    <PMID>17148023</PMID>
  </reference>
  <reference>
    <citation>Ream JM, Dillman JR, Adler J, Khalatbari S, McHugh JB, Strouse PJ, Dhanani M, Shpeen B, Al-Hawary MM. MRI diffusion-weighted imaging (DWI) in pediatric small bowel Crohn disease: correlation with MRI findings of active bowel wall inflammation. Pediatr Radiol. 2013 Sep;43(9):1077-85. doi: 10.1007/s00247-013-2712-3. Epub 2013 Aug 16.</citation>
    <PMID>23949929</PMID>
  </reference>
  <reference>
    <citation>Dillman JR, Smith EA, Sanchez R, Adler J, Fazeli S, Zhang B, Davenport MS. DWI in Pediatric Small-Bowel Crohn Disease: Are Apparent Diffusion Coefficients Surrogates for Disease Activity in Patients Receiving Infliximab Therapy? AJR Am J Roentgenol. 2016 Nov;207(5):1002-1008. Epub 2016 Aug 9.</citation>
    <PMID>27505635</PMID>
  </reference>
  <reference>
    <citation>Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986 Nov;161(2):401-7.</citation>
    <PMID>3763909</PMID>
  </reference>
  <reference>
    <citation>Freiman M, Perez-Rossello JM, Callahan MJ, Bittman M, Mulkern RV, Bousvaros A, Warfield SK. Characterization of fast and slow diffusion from diffusion-weighted MRI of pediatric Crohn's disease. J Magn Reson Imaging. 2013 Jan;37(1):156-63. doi: 10.1002/jmri.23781. Epub 2012 Aug 24.</citation>
    <PMID>22927342</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.</citation>
    <PMID>18929686</PMID>
  </reference>
  <reference>
    <citation>Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991 May;12(4):439-47.</citation>
    <PMID>1678008</PMID>
  </reference>
  <reference>
    <citation>Someya N, Endo MY, Fukuba Y, Hayashi N. Blood flow responses in celiac and superior mesenteric arteries in the initial phase of digestion. Am J Physiol Regul Integr Comp Physiol. 2008 Jun;294(6):R1790-6. doi: 10.1152/ajpregu.00553.2007. Epub 2008 Apr 2.</citation>
    <PMID>18385466</PMID>
  </reference>
  <reference>
    <citation>Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes ThÃ©rapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989 Jul;30(7):983-9.</citation>
    <PMID>2668130</PMID>
  </reference>
  <reference>
    <citation>Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014 Jan;63(1):88-95. doi: 10.1136/gutjnl-2013-304984. Epub 2013 Aug 23.</citation>
    <PMID>23974954</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only de-identified data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

